Overview

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Status:
RECRUITING
Trial end date:
2027-08-24
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
Phase:
PHASE1
Details
Lead Sponsor:
SystImmune Inc.